Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug–drug interaction study

OBJECTIVE: To evaluate the impact of two calcitonin gene–related peptide (CGRP)‐targeted monoclonal antibodies (mAbs), erenumab and galcanezumab, on the pharmacokinetic (PK) profile, safety, and tolerability of ubrogepant. BACKGROUND: People taking CGRP‐targeted mAbs for migraine prevention sometime...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Headache
Hlavní autoři: Jakate, Abhijeet, Blumenfeld, Andrew M., Boinpally, Ramesh, Butler, Matthew, Borbridge, Lisa, Contreras‐De Lama, Janette, McGeeney, Danielle, Periclou, Antonia, Lipton, Richard B.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2021
Témata:
Research Submissions
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8252052/
https://ncbi.nlm.nih.gov/pubmed/33818780
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/head.14095
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky